ArticleScientific reports2025
Global trends and age-period-cohort effects of chronic respiratory disease mortality attributed to industrial gaseous pollutants from 1990 to 2021.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interventions for reducing caregiver burden in chronic dyspnea: a meta-analysis.Frontiers in public health · 2025Pooled it
- Association between air pollutant exposure and ocular surface, anterior and middle segment and fundus eye diseases: epidemiological and mechanism evidence.Eye (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The increasing concern over chronic respiratory diseases (CRDs) caused by industrial pollution from particulate matter, gases, and fumes (PMGF) highlights the critical need for a comprehensive understanding of its spatiotemporal trends to mitigate work-related respiratory disorders effectively. Data from the Global Burden of Disease 2021 were extracted to analyze the mortality of occupational PMGF-attributed CRD. The joinpoint regression model was employed to illustrate its trends in age-standardized mortality rate (ASMR) from 1990 to 2021, facilitating the calculation of average annual percentage changes (AAPCs). The age-period-cohort (APC) model was used to isolate and quantify the contributions of age, period, and cohort effects to the observed temporal trends in mortality rates. From 1990 to 2021, the ASMR of PMGF attributed-CRD decreased from 21.74 (13.34, 30.11) to 12.84 (7.80, 18.20), with an AAPC of -1.69 (-1.82, -1.56). A sharper negative AAPC was detected in females, pneumoconiosis cases, middle SDI region, and Southeast Asia, East Asia & Oceania. In addition, some positive AAPCs appeared in low-middle SDI, South Asia, and high-income nations for females. Although the Western Pacific witnessed the steepest ASMR declines, a rising ASMR was noted in Nordic and American female COPD patients, with increasing pneumoconiosis ASMR in the Middle East and North Africa. The total age-specific mortality increased, with a decrease observed in both period and cohort effect, more pronounced among females. COPD mortality exhibited a steeper decline than pneumoconiosis in the period and cohort RR, but not for females. The low-middle SDI region and South Asia led in age-specific CRD mortality, whereas the period and cohort RR experienced the largest reduction in the high-middle SDI region and Southeast Asia, East Asia & Oceania. However, the period and cohort RR showed the weakest attenuation in Sub-Saharan Africa and South Asia. Over the past 32 years, progress has been made in managing industrial PMGF pollution-related CRD; however, challenges persist, particularly among sub-Saharan Africans, South Asian women, pneumoconiosis cases in the Middle East and North Africa, and female COPD patients in high-income nations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.